Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2024-03-25 AGM Information
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
关于召开2024年第一次临时股东大会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the 2024 first extraordinary general meeting of shareholders (临时股东大会) for Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items to be discussed, and procedural information for shareholders. The document does not contain financial statements or detailed financial analysis but serves as an official announcement for the meeting and its agenda. The length is 3522 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or related to the Annual or Extraordinary General Meeting, including notices of meetings.
2024-03-25 Chinese
独立董事候选人声明与承诺（舒霖）
Board/Management Information Classification · 95% confidence The document is a statement and commitment by an independent director candidate for Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the candidate's qualifications, independence, and compliance with relevant laws and regulations. There is no financial data, no report or announcement of financial results, no voting results, no management changes, and no regulatory filings of other types. The document is a declaration related to board/management information, specifically about a director candidate's qualifications and commitments. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2024-03-25 Chinese
浙江海昇药业股份有限公司承诺管理制度
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the adoption of a 'Commitment Management System' by the company's board of directors. It includes details about the system's purpose, scope, and procedures, referencing relevant laws and regulations. The document is relatively short (1850 characters) and does not contain financial statements, audit results, or detailed financial data. It is not a report itself but rather a regulatory announcement about corporate governance and compliance policies. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure that does not fall into other specific categories.
2024-03-25 Chinese
独立董事提名人声明与承诺(舒霖）
Board/Management Information Classification · 95% confidence The document is a formal announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. nominating an independent director candidate for the company's board. It includes detailed statements and commitments regarding the candidate's qualifications, independence, and compliance with relevant laws and regulations. There is no financial data, no report or presentation content, and no mention of voting results or meeting materials. The document is a regulatory announcement related to board management but specifically about the nomination of an independent director rather than a change in board members or senior management. This fits best under Board/Management Information (MANG) as it concerns board composition and governance-related personnel nomination.
2024-03-25 Chinese
第三届监事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the meeting date, attendance, and voting results on several proposals related to adjustments in the use of raised funds from a public stock issuance. The document does not contain financial statements or detailed financial data but rather reports on decisions made in a board meeting. It is not an annual or interim report, audit report, or earnings release. It is not a call transcript or investor presentation. The document is a formal announcement of board meeting resolutions, which fits best under Board/Management Information (MANG). The document length is short (1762 characters), and it is not merely announcing the publication of a report but reporting meeting resolutions. Therefore, the appropriate classification is MANG with high confidence.
2024-03-25 Chinese
浙江海昇药业股份有限公司董事会审计委员会工作细则
Governance Information Classification · 95% confidence The document is titled '董事会审计委员会工作细则' which translates to 'Board Audit Committee Working Rules'. It details the composition, responsibilities, and procedures of the audit committee under the board of directors. It includes sections on personnel, duties, meeting rules, and other governance-related matters. There is no financial data, no financial statements, no earnings information, no voting results, no legal proceedings, no capital changes, and no report publication announcement. The document is a governance-related internal rules document for the audit committee, which fits the definition of Governance Information (CGR). The document length is 2558 characters, which is relatively short but contains substantive governance content, not just an announcement or certification. Therefore, the best classification is CGR with high confidence.
2024-03-25 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.